Jonathan Biller

Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA.

Celgene Ltd. engages in the development of human pharmaceuticals and agrochemicals. It focuses on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. The company was founded on June 2, 2015 and is headquartered in Uxbridge, the United Kingdom.

Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.

Part of Bristol Myers Squibb Co., Celgene Europe Ltd. is a British company that engages in research and development in pharmaceutical products. The private company is based in Middlesex, UK.

Part of Bristol Myers Squibb Co., Celgene UK Holdings Ltd. functions as an investment holding private company. The company is based in London, UK.

Part of Bristol Myers Squibb Co., Celgene UK Manufacturing (II) Ltd. functions as an investment holding private company. The company is based in London, UK.

Part of Bristol Myers Squibb Co., Celgene UK Manufacturing Ltd. functions as an investment holding private company. The company is based in London, UK.